(Q32052939)

5 July 2017

title

Successful use of donepezil for the treatment of dementia with Lewy bodies (English)

1 reference

dementia with Lewy bodies

5 July 2017

1 reference

1 reference

C H Rojas-Fernandez

1

1 reference

5 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

Annals of Pharmacotherapy

5 July 2017

published in

1 reference

5 July 2017

volume

35

1 reference

5 July 2017

issue

2

1 reference

5 July 2017

page(s)

202-205

1 reference

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

5 July 2017

cites work

1 reference

Dementia with Lewy bodies: review and pharmacotherapeutic implications

21 January 2018

1 reference

Topography, Extent, and Clinical Relevance of Neurochemical Deficits in Dementia of Lewy Body Type, Parkinson's Disease, and Alzheimer's Disease

21 January 2018

1 reference

Lewy bodies and response to tacrine in Alzheimer's disease.

21 January 2018

1 reference

Dementia with Lewy bodies: response of delirium-like features to donepezil.

21 January 2018

1 reference

Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.

21 January 2018

1 reference

Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study

21 January 2018

1 reference

Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

21 January 2018

1 reference

Cholinesterase inhibitors: A new class of psychotropic compounds

21 January 2018

1 reference

Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited

21 January 2018

1 reference

Acetylcholine in mind: a neurotransmitter correlate of consciousness?

21 January 2018

1 reference

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

21 January 2018

1 reference

Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease.

21 January 2018

1 reference

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

21 January 2018

1 reference

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

21 January 2018

1 reference

Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies

21 January 2018

1 reference

Spectrum of disease in vascular cognitive impairment.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.10192

1 reference

5 July 2017

1 reference